Antengene initiates Phase II Dose Expansion Study of Claudin 18.2 ADC ATG-022 in China and Australia

CAR-T Digest - August 2020

18 Mar 2024: Antengene initiates Phase II Dose Expansion Study of Claudin 18.2 ADC ATG-022 in China and Australia

Antengene Corporation has initiated the dose expansion portion of the Phase II CLINCH study of ATG-022 (Claudin 18.2 ADC]) in patients with gastric cancer or other solid tumors
Claudin 18.2 is often overexpressed in primary malignant tumors such as gastric, esophageal, cholangiocarcinoma, and pancreatic cancers
The CLINCH trial is backed by robust preclinical evidence and promising initial clinical results, including one PR and CR in two patients with metastatic gastric cancer
In May 2023, the FDA consecutively granted two Orphan Drug Designations to ATG-022 for the treatment of pancreatic cancer and gastric cancer, separately